GlobeNewswire by notified

Align Technology Reaches 6 Millionth Invisalign® Patient Milestone With Tween Patient From China

Share
  • 12-year old Yuzhe Wang from Beijing, China is in treatment with Invisalign trained doctor Jiawei Wo using Invisalign Comprehensive with Mandibular Advancement
  • Accelerating adoption of Invisalign clear aligner treatment globally reflects Align’s continued investment in product innovation and commitment to international expansion

BEIJING and SAN JOSE, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (NASDAQ: ALGN) today announced that over 6 million patients have begun treatment with Invisalign - the most advanced clear aligner system in the world, including 1.4 million teenage patients*. This is a significant milestone for the company and the over 150,000 Invisalign-trained doctors worldwide, reflecting accelerating adoption of Invisalign treatment by adults and teens alike.

The 6 millionth Invisalign patient, Yuzhe Wang, is a 12-year-old student of the International School of Beijing, who began treatment in October 2018 using Invisalign Comprehensive with Mandibular Advancement treatment with Dr. Jiawei Wo from Yuxueyuan Dental clinic. Dr. Wo is a Gold Invisalign trained doctor based in Beijing, China who specializes in pediatric orthodontics. 

Dr. Wo prescribed Invisalign clear aligner therapy to his patient Yuzhe Wang to address her class II type of teeth misalignment and because it fit well into her busy, student lifestyle: “Invisalign treatment with Mandibular Advancement is great, because it moves the lower jaw forward, while simultaneously aligning the teeth. With the Invisalign system, my patients need much fewer appointments than with traditional orthodontic appliances. This allows them to continue their studies and daily activities without interruption”.

“We are delighted to be celebrating another significant milestone with Invisalign trained doctors and their patients. This achievement is a reflection of growing demand for Invisalign clear aligners from international markets, especially China, which is our second largest market, nearly doubling each year since the Invisalign system was launched in China back in 2011. I would like to thank Dr. Jiawei Wo and all of the Invisalign trained doctors around the world for helping us make Invisalign treatment the clear aligner orthodontic method of choice among teens such as Yuzhe, as well as for giving our patients a chance to have beautiful, straight teeth and smile with confidence” – said Joe Hogan, Align Technology president and CEO.

Julie Tay, Align Technology senior vice president and managing director, Asia Pacific recognized the importance of the 6 millionth Invisalign patient coming from China: “I was absolutely delighted and proud to hear that 6 millionth patient is from Asia Pacific. China is our fastest growing country market with approximately 70% annual growth rate**. I believe there is an enormous opportunity in the region for Invisalign providers to treat millions of young patients like Yuzhe. I would like to thank Dr. Wo for his confidence in treating Yuzhe with the Invisalign system, and Yuzhe’s parents for trusting that it is the best solution for their daughter.”

In support of this major milestone for the company, Yuzhe will be featured in an upcoming Invisalign global campaign, entitled “6 Million Invisalign Smiles” that will follow Yuzhe and her family through her Invisalign treatment journey. The campaign will highlight key reasons why she and her parents decided to choose Invisalign clear aligners to help her achieve a new, beautiful smile. 

To mark this significant milestone, Align Technology continues its commitment to Operation Smile and the non-profit’s global mission of providing free surgeries to children and adults born with cleft lip and cleft palate. Align will donate to the organization. To date, Align has given close to $1 million to Operation Smile which was founded in 1982 and has provided hundreds of thousands of life-changing surgeries.

*Q3 2018 Data. **Q3 2018 Data. 

About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, and iTero® intraoral scanners and services. Align’s products help dental professionals achieve the clinical results they expect and to deliver effective, cutting-edge dental options to their patients. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about iTero digital scanning system, please visit www.itero.com.

About Operation Smile
Operation Smile has provided hundreds of thousands of safe, essential surgeries for patients born with cleft lip and cleft palate. With more than three decades of expertise, Operation Smile creates solutions that deliver free surgery to people where it’s needed most. As one of the largest medical volunteer-based nonprofits, Operation Smile has mobilized thousands of medical volunteers from a wide range of medical specialties from more than 80 countries. Operation Smile engages public-private partnerships to advance health care delivery, trains local medical professionals to provide surgical care for patients in their communities, donates critical medical equipment and supplies, and increases access to surgical care so that everyone living with cleft is treated. Visit www.operationsmile.org, find us on Facebook or follow us on Twitter.

Images Available: 

http://www.globenewswire.com/NewsRoom/AttachmentNg/d92999b2-ac13-465e-9b54-ffe53c9dc806

http://www.globenewswire.com/NewsRoom/AttachmentNg/02bf839b-05d2-4c72-8d56-8bfd630f5aef

Video Available: https://www.youtube.com/watch?v=l-fh9vScJYQ&feature=youtu.be

Align Technology
Madelyn Homick
mhomick@aligntech.com

Zeno Group
Sarah Johnson
sarah.johnson@zenogroup.com

Source: Align Technology

News Provided by GlobeNewswire

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors23.4.2024 19:42:34 CEST | Press release

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of disease Novartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, brain and pancreatic cancers Basel, April 23, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and appro

Grant of warrants23.4.2024 19:20:21 CEST | Press release

23 April 2024 Announcement no. 9 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, April 23, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the annual general meeting’s resolution on April 27, 2023, to issue a total of 4,000,000 warrants to members of the Executive Management. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 1.23 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are issued in accordance with section 18 a of the Articles of Association. Half of the warrants vest over a 2-year period, and the remaining half upon completion of a qualified capital raise in the Company with terms of qualification (including timing and amount of proceeds) to be defined by the Board of Directors. The warrants are otherwise subject to the Company’s incentive warrant program as included in Appendix 1 o

TrueCommerce leverer globale e-fakturerings- og CTC-løsninger til virksomheder, der har udfordringer med overholdelse23.4.2024 19:10:28 CEST | pressemeddelelse

Virksomheden er ene om at tilbyde en global løsning, der omfatter e-fakturering, CTC-løsninger og et omfattende EDI-netværk, alt sammen problemfritintegreret med B2B e-handels- og ERP-systemer KØBENHAVN, Danmark, April 23, 2024 (GLOBE NEWSWIRE) -- TrueCommerce, en global leverandør af forsyningskæde- og handelspartnerforbindelser, integration og løsninger via flere kanaler, har i dag givet meddelelse om sin globale løsning til e-fakturering og Continuous Transaction Controls (CTC), der gør det muligt for organisationer at holde trit med de konstant skiftende juridiske krav overalt i verden og understøtter elektronisk fakturering, som opfylder de gældende krav. TrueCommerce er en global markedsaktør, der understøtter både e-fakturering og CTC og giver adgang til et omfattende globalt EDI-netværk samt B2B e-handel og ERP-integration. På grund af kompleksiteten i at navigere i et landskab af stadigt skiftende landespecifikke e-faktureringskrav og deadlines, står virksomheder over for en s

Festi hf.: Financial results for Q1 202423.4.2024 19:02:17 CEST | Press release

Key findings Sale of goods amounted to ISK 32,223 million, compared to ISK 29,484 million in the previous year, an increase of 9.3% between years.Gross profit from sales of goods and services amounted to ISK 7,033 million, an increase of 806 million or 12.9% between years.Profit Margins from sales of goods and services were 21.8% and increases by 0.7 p.p. from Q1 2023 but decreases by 1.2 p.p. from Q4 2023.Salaries and other personnel expenses increase by 7.5% and full-time equivalents by 2.5%.EBITDA amounted to ISK 1,898 million compared to ISK 1,401 million in Q1 2023, increase of 35.5% between years. Profit for the quarter amounted to ISK 202 million, or 2.9% of margin, a turnaround of ISK 293 million YoY.Net cash from operating activities was ISK 538 million or 7.6% of margin, compared to ISK 1,238 million last year.Equity at the end of Q1 2024 amounted to ISK 35,140 million with an equity ratio of 36.0%. EBITDA forecast for the year 2024 is raised by ISK 300 million and is now ISK

ASM reports first quarter 202423.4.2024 18:00:00 CEST | Press release

Almere, The Netherlands April 23, 2024, 6 p.m. CET Solid start of the year, Q1 orders supported by GAA and HBM ASM International N.V. (Euronext Amsterdam: ASM) today reports its Q1 2024 results (unaudited). Financial highlights € millionQ1 2023Q4 2023Q1 2024 New orders 647.4 677.5 697.9 yoy change % at constant currencies (6%) (14%) 10% Revenue 710.0 632.9 639.0 yoy change % at constant currencies 40% (7%) (8%) Gross profit margin % 49.4 % 47.2 % 52.9 % Adjusted gross profit margin 1 51.1 % 47.9 % 52.9 % Operating result 204.2 131.5 187.1 Operating result margin % 28.8 % 20.8 % 29.3 % Adjusted operating result 1 221.2 141.0 191.8 Adjusted operating result margin 1 31.2 % 22.3 % 30.0 % Net earnings 380.4 90.9 173.1 Adjusted net earnings 1 183.0 100.3 178.9 1 Adjusted figures are non-IFRS performance measures (previously referred to as "normalized"). Refer to Annex 3 for a reconciliation of non-IFRS performance measures. New orders of €698 million in Q1 2024 increased by 10% at constant

HiddenA line styled icon from Orion Icon Library.Eye